Budesonide Global Market Report 2026

Budesonide is a corticosteroid drug used to decrease inflammation in conditions like asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases (Crohn's disease, ulcerative colitis), and allergic rhinitis. It functions by suppressing the immune system and reducing inflammation in the airways or digestive tract.

The primary forms of budesonide include inhalation powder, aerosols, injectable suspensions, tablets, and capsules. Inhalation budesonide powder is a corticosteroid medication administered through a dry powder inhaler to alleviate inflammation in the airways for certain conditions. Budesonide is available via hospital pharmacies, retail pharmacies, and online pharmacies, and it is utilized for a range of applications, including treatment of nasal disorders, inflammatory bowel disease, respiratory conditions, and other uses.

Tariffs have affected the budesonide market by increasing the cost of imported active pharmaceutical ingredients and inhalation device components used in respiratory therapies. The impact is most visible in inhalation powder and aerosol segments, where device precision and formulation quality are critical. Regions such as North America and Europe have experienced higher input costs due to reliance on cross border pharmaceutical and device supply chains. Rising tariff related expenses have influenced pricing strategies, procurement planning, and product availability. However, tariffs have encouraged local manufacturing, expanded domestic formulation capacity, and strengthened regional generic drug supply chains over the long term.

The budesonide market research report is one of a series of new reports from The Business Research Company that provides budesonide market statistics, including budesonide industry global market size, regional shares, competitors with a budesonide market share, detailed budesonide market segments, market trends and opportunities, and any further data you may need to thrive in the budesonide industry. This budesonide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The budesonide market size has grown strongly in recent years. It will grow from $10.26 billion in 2025 to $10.88 billion in 2026 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to rising asthma and copd prevalence, widespread corticosteroid adoption, expansion of inhalation therapies, increased ibd diagnosis, improved drug delivery technologies.

The budesonide market size is expected to see strong growth in the next few years. It will grow to $13.72 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to aging population, rising chronic inflammatory diseases, growth in generic drug usage, expansion of home-based therapies, increasing respiratory disease burden. Major trends in the forecast period include rising use of inhaled corticosteroids in chronic respiratory care, increasing adoption in inflammatory bowel disease management, growing preference for targeted localized steroid therapy, expansion of generic budesonide formulations, increased use in long-term maintenance therapy.

The rising prevalence of respiratory diseases is expected to drive the growth of the budesonide market in the coming years. Respiratory diseases are medical conditions that affect the organs and tissues responsible for gas exchange in air-breathing organisms. The increase in respiratory diseases is largely attributed to growing air pollution, especially exposure to particulate matter and allergens, which significantly contributes to the prevalence of asthma and chronic obstructive pulmonary disease (COPD). Budesonide is used to manage respiratory conditions such as asthma and COPD by reducing inflammation, improving airflow, and preventing symptoms like wheezing and shortness of breath. For example, in August 2025, the Centers for Disease Control and Prevention, a Switzerland-based public health agency, reported that 90% of the country's 4.9 trillion dollars in annual healthcare expenditures are linked to individuals with chronic and mental health conditions, with over 84,000 Americans dying each year from heart disease or stroke, and costs associated with cardiovascular diseases projected to reach approximately 2 trillion dollars by 2050. Consequently, the increasing prevalence of respiratory diseases is expected to propel the growth of the budesonide market.

Major companies operating in the budesonide market are emphasizing innovations in respiratory treatments, such as oral therapy, to enhance patient convenience, improve treatment adherence, and broaden therapeutic options for managing asthma and other respiratory disorders. Oral therapy budesonide is a formulation administered by mouth, primarily used to address inflammatory conditions. For example, in February 2024, Takeda Pharmaceuticals, a Japan-based pharmaceutical company, announced that the Food and Drug Administration (FDA), a US-based federal agency, had approved EOHILIA, a budesonide oral suspension, as the first and only FDA-approved oral treatment for patients aged 11 and above with eosinophilic esophagitis (EoE). Moreover, the FDA authorized EOHILIA 2 mg twice daily based on efficacy and safety results from two multicenter, randomized, double-blind, parallel-group, placebo-controlled 12-week trials in individuals aged 11 to 56 with EoE.

In March 2023, Cheplapharm Arzneimittel GmbH, a Germany-based pharmaceutical company, acquired the commercial rights to PULMICORT FLEXHALER in the U.S. from AstraZeneca for an undisclosed amount. This acquisition is intended to strengthen and diversify Cheplapharm's portfolio by obtaining the rights to PULMICORT FLEXHALER, a well-established budesonide-based asthma treatment. Furthermore, it enables the company to expand its footprint in the U.S. pharmaceutical sector while ensuring continued product availability through collaborations with local distributors. AstraZeneca, a UK-based biopharmaceutical company, focuses on developing and marketing PULMICORT for respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD), which contain budesonide.

Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

North America was the largest region in the budesonide market in 2025. The regions covered in the budesonide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the budesonide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The budesonide market consists of sales of nebulizer suspension, inhalers, and nasal sprays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Budesonide Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses budesonide market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for budesonide ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The budesonide market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Inhalation Powder; Aerosols; Tablets And Capsules
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By Application: Nose Disease Treatment; Inflammatory Bowel Disease Treatment; Respiratory Disease Treatment; Other Applications
• Subsegments:
• 1) By Inhalation Powder: Dry Powder Inhalers (DPI); Soft Mist Inhalers (SMI)
• 2) By Aerosols: Metered-Dose Inhalers (MDI); Breath-Activated Inhalers
• 3) By Tablets And Capsules: Oral Tablets; Oral Capsules
• Companies Mentioned: AstraZeneca AB; Novartis AG; Takeda Pharmaceuticals Company Limited; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz AG; Aurobindo Pharma Limited; Chiesi Farmaceutici S.p.A.; Cipla Limited; Lupin Limited; Orion Corporation; Salix Pharmaceuticals Inc.; Synmosa Biopharma Corporation; Cosmo Pharmaceuticals N.V.; Skyepharma Holdings Inc.; Manus Aktteva Biopharma LLP; Cennet Biopharma Private Limited; Santarus Inc.; SiNi Pharma Private Limited; Shanghai Sine Promod Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.